Dear Mrs Gauer,

Please find enclosed our Sanofi answer to the questionnaire on COVID-19 vaccines.

In line with our meeting discussion, the answers primarily focus on our most advanced vaccine in development: the recombinant protein vaccine.

The second vaccine we have in development in collaboration with is mentioned only in selected questions.

We would be pleased to provide you any further explanation needed and follow-up our constructive discussion in the coming weeks.

Best regards

EU Transparency Register: 6129462764-77

Please consider the environment before printing this email

EXTERNAL : Real sender is @ec.europa.eu

Dear
In follow-up to our call of yesterday, please find attached a letter by Céline Gauer, together with a questionnaire.

Kind regards

European Commission | Secretariat-General
BERL B-1049 Brussels/Belgium | Tel

Disclaimer: This is an informal e-mail which should not be registered. The above text cannot be regarded as an official position of the European Commission; any views expressed are exclusively those of the author. It is intended solely for the person to whom it is addressed and may contain confidential information.